PMID- 28770960
OWN - NLM
STAT- MEDLINE
DCOM- 20180808
LR  - 20190221
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 14
DP  - 2017 Jul
TI  - Expression of miR-195 in laryngeal squamous cell carcinoma and its effect on 
      proliferation and apoptosis of Hep-2.
PG  - 3232-3238
LID - 13146 [pii]
AB  - OBJECTIVE: To investigate the expression of miR-195 and its relationship with 
      clinicopathological characteristics in laryngeal squamous cell carcinoma (LSCC), 
      and to explore its effect and possible mechanism on proliferation and apoptosis 
      of Hep-2. PATIENTS AND METHODS: Real-time fluorescence quantitative PCR was used 
      to detect the expression of miR-195 in laryngeal carcinoma tissues and adjacent 
      normal tissues from 98 cases. Dual-luciferase reporter plasmid with Bcl-2 wild 
      type and mutant type 3' untranslated region was created to verify the target of 
      miR-195 by luciferase assay. After Hep-2 cells were transfected with 
      miR-195/Bcl-2, miR-195, Bcl-2 siRNA and negative control by lipofectamine, the 
      protein expression of Bcl-2 was detected by Western blot analysis. The 
      proliferation and apoptosis of Hep-2 were detected by MTS method and flow 
      cytometry, respectively. RESULTS: Compared with adjacent normal tissues, the 
      expression of miR-195 was lower in laryngeal carcinoma tissues (p < 0.01). The 
      low expression of miR-195 was positively correlated with distant metastasis and 
      clinical stage (p < 0.05). The average survival time of patients with low 
      expression was shorter than those with high expression by Kaplan-Meier method (p 
      < 0.01). Multivariate Cox analysis showed that miR-195 expression and lymph node 
      metastases were independent prognostic factors (p < 0.05). CONCLUSIONS: The 
      expression of miR-195 was significantly decreased in laryngeal carcinoma tissues, 
      which was closely related to the clinicopathological characteristics of LSCC. 
      miR-195 may inhibit the proliferation and promote the apoptosis of Hep-2 by 
      regulating Bcl-2 expression, which as an anti-oncogene could have the potential 
      to be a therapeutic strategy in the treatment of LSCC.
FAU - Shuang, Y
AU  - Shuang Y
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology; Tianjin Medical 
      University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin Cancer Institute; National Clinical Research Center of Cancer; 
      Tianjin, China. zhanglun_tijmu@163.com.
FAU - Li, C
AU  - Li C
FAU - Zhou, X
AU  - Zhou X
FAU - Huang, Y-W
AU  - Huang YW
FAU - Zhang, L
AU  - Zhang L
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (MIRN195 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Female
MH  - Head and Neck Neoplasms/genetics/*pathology
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - MicroRNAs/*physiology
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-2/analysis
MH  - Squamous Cell Carcinoma of Head and Neck
EDAT- 2017/08/05 06:00
MHDA- 2018/08/09 06:00
CRDT- 2017/08/04 06:00
PHST- 2017/08/04 06:00 [entrez]
PHST- 2017/08/05 06:00 [pubmed]
PHST- 2018/08/09 06:00 [medline]
AID - 13146 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3232-3238.